Pterostilbene for Cognitive Function
Cognitive benefits remain hypothetical in humans.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- Studied at 50-250 mg/day for 6-8 weeks; no cognitive endpoint has been measured in humans
- Expected timeframe
- Not established
Protocol
- form
- Pterostilbene, a dimethylated resveratrol analogue with roughly 80% oral bioavailability
- duration
- Human trials ran 6-8 weeks and measured lipids, blood pressure and glucose
- co factor
- Evidence is insufficient. The cognitive rationale is entirely preclinical: pterostilbene crosses the blood-brain barrier more readily than resveratrol, and rodent studies show improved working memory in aged animals, reduced hippocampal oxidative stress, modulation of dopamine signalling, and reduced amyloid pathology in Alzheimer models. Joseph and colleagues found pterostilbene improved cognitive performance in aged rats and correlated it with hippocampal accumulation. No human trial has measured memory, attention, processing speed or any neuropsychological outcome after pterostilbene, at any dose or duration.
- titration
- Not applicable - no cognitive dose-response exists in humans
- starting dose
- Not established. Human trials used 50-250 mg/day of pterostilbene, and none assessed cognition
Evidence
What the studies say
No studies are yet linked to both Pterostilbene and Cognitive Function.
Safety
Caveats
Rodent cognition studies are a weak basis for human claims - the translation rate from aged-rat memory findings to human cognitive benefit is very poor. For cognitive health the evidence sits with physical exercise, sleep, treating hearing loss, controlling blood pressure and diabetes in midlife, not smoking, limiting alcohol and social engagement. Progressive memory problems or cognitive change affecting function need medical assessment, since B12 deficiency, hypothyroidism, depression, sleep apnoea and anticholinergic medication burden are common reversible contributors. Safety of pterostilbene: the key flag is that 250 mg/day increased LDL cholesterol in the Riche randomised trial - relevant because vascular risk factors drive cognitive decline, so raising LDL works against the goal. Human safety data extend to roughly 8 weeks only, so long-term safety is unknown, and no upper intake level has been established; do not exceed the studied range. Pterostilbene inhibits cytochrome P450 enzymes in vitro and may have antiplatelet activity, so use caution with anticoagulants, antiplatelet drugs and narrow-therapeutic-index medication, and stop before surgery. Avoid in pregnancy and breastfeeding, since no safety data exist.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.